Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: a single center perspective
暂无分享,去创建一个
N. Gebauer | D. Rades | H. Lehnert | C. Thorns | A. Czerwińska | K. Luley | V. Bernard | H. Biersack | Tim Tristan Hardel | Janina Schemme